Dixit A, et al. - Researchers conducted this retrospective observational study of patients aged <18 years who received oral or intravenous moxifloxacin between January 2011 and July 2016, to determine the safety of systemic moxifloxacin therapy in children. Two hundred twenty-one patients receiving 300 courses of moxifloxacin were analyzed. During pediatric moxifloxacin therapy, adverse events (AEs) were relatively common but were rarely serious enough to require premature discontinuation. With monitoring, including evaluation for corrected QT interval (QTc) prolongation, and guidance from infectious disease specialists, the drug could be safely administered to most children.